Access cutting-edge gastroesophageal adenocarcinoma treatment through this clinical trial at a research site in New York. Study-provided care at no cost to qualified participants.
Access gastroesophageal adenocarcinoma specialists in New York at no cost
This study follows strict safety protocols and ethical guidelines
All study-related gastroesophageal adenocarcinoma treatment provided free
This is a phase 1/2, multicenter, open-label umbrella platform study that will evaluate the safety and tolerability of sacituzumab tirumotecan with pembrolizumab and fluoropyrimidine chemotherapy for the first-line (1L) treatment of participants with locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric, gastroesophageal junction, or esophageal adenocarcinoma. This substudy will have two phases: a safety lead-in phase and an efficacy phase.
Sponsor: Merck Sharp & Dohme LLC
Check if you qualify for this gastroesophageal adenocarcinoma clinical trial in New York, NY
If you're searching for gastroesophageal adenocarcinoma treatment options in New York, NY, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our New York research site is actively enrolling participants for this clinical trial. You'll receive care from experienced gastroesophageal adenocarcinoma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.